首页> 外国专利> Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor

Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor

机译:IL-15和MAP激酶抑制剂抑制树突状细胞驱动的调节性T细胞活化并增强肿瘤抗原特异性T细胞应答

摘要

The invention involves the discovery that if dendritic cells loaded with a tumor antigen are cultured in interleukin-15 (IL-15), or if T cells activated by the dendritic cells are cultured in IL-15, Treg activity that is specific for the tumor antigen is reduced. This reduction in Treg activity results in an increase in anti-tumor immune response. Another embodiment of the invention involves the discovery that incubating dendritic cells with a MAP kinase inhibitor in combination with IL-15 gives synergistic benefits when the dendritic cells are used to activate T cells. Dendritic cell and T cell compositions incubated with IL-15 or a MAP kinase inhibitor are provided.
机译:本发明涉及以下发现:如果将负载有肿瘤抗原的树突细胞培养在白介素15(IL-15)中,或者如果将被树突细胞激活的T细胞培养在IL-15中,则对肿瘤具有特异性的Treg活性抗原减少。 Treg活性的这种降低导致抗肿瘤免疫应答的增加。本发明的另一个实施方案涉及发现,当树突状细胞用于激活T细胞时,将树突状细胞与MAP激酶抑制剂与IL-15组合孵育会产生协同作用。提供了与IL-15或MAP激酶抑制剂一起孵育的树突细胞和T细胞组合物。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号